http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2361578-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d75ff09376a7649497462b282d246ffe |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
| filingDate | 2004-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c35d9d5d06549ef60d1247d2f9c95953 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bd3468edbfaad4d12918c39bfc97594 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61397bcd7cd4c0a04b1299161f8eeeca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_425ab7c33c759635fb53109765ad1899 |
| publicationDate | 2011-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2361578-T3 |
| titleOfInvention | DRUG-LIPID FORMULATIONS FOR DIRECTED ADMINISTRATION OF DRUGS TO IMMUNE MYELOID AND LINFOID CELLS. |
| abstract | A lipid-drug complex comprising a drug and further comprising director ligands on an outer surface that specifically bind to the surface of an immune cell at least a combination of the following markers: CD209 and CD4; or CD209 and CD45R0 in which said drug is an immunomodulatory agent that is activated in an immune cell to which said directing ligand is directed and in which said directing ligand is a monoclonal antibody. |
| priorityDate | 2003-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 411.